Pfizer raked in US$81 billion revenue – full 2021 year

Please share this story - thanks

By Michael Coles

Drug maker Pfizer enjoyed full year revenues in 2021 totalling US$81.3 billion according to a press release (or here) issued by the firm Tuesday announcing its annual financial report.

During the fourth quarter of 2021 the firm brought in revenues of more than $23 billion, reflecting growth of 106% on the previous (2020) fourth quarter.

In a guidance note to the market, the maker of covid vaccines said it expects to see revenues climb for the 2022 year to $98 billion. It says sales of its Comirnaty vaccines will raise $32 billion this year.

During full-year 2021, Pfizer paid $8.7 billion of cash dividends to its shareholders, or $1.56 per share of common stock, which represents an increase in dividends per share of 3% compared to full-year 2020. Pfizer shares at time of publication stood at $51.70 per share.

The company also said its ‘effective tax rate’ is just 6.5% on profits.

The New Zealand government added to Pfizer’s income to the tune of $1 billion.

On page 10 of its press release Pfizer states: “In December 2021, Pfizer and BioNTech shared that following a routine review by the external independent Data Monitoring Committee (DMC), the companies will amend the clinical study evaluating the safety, tolerability, and immunogenicity of two doses of BNT162b2 in children 6 months to under 5 years of age.

“Compared to the 16- to 25-year-old population in which high efficacy was demonstrated, non-inferiority [no worse] was met for the 6- to 24-month-old population but not for the 2- to under 5-year-old population in this analysis.

“The study, which is ongoing and remains blinded, will now include evaluating a third dose at least two months after the second dose of the two-dose series to provide high levels of protection in this young age group.

“Pfizer and BioNTech also plan to evaluate a third dose of the 10 μg formulation in children 5 to under 12 years of age.

“In January 2022, Pfizer and BioNTech announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age.

“The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine.

“The study will draw upon some participants from the companies’ Phase 3 COVID-19 booster study and is part of their ongoing efforts to address Omicron and determine the potential need for variant-based vaccines.”

Please share this story - thanks